Mutual of America Capital Management LLC Sells 1,338 Shares of Edwards Lifesciences Corporation $EW

Mutual of America Capital Management LLC decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 1.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,401 shares of the medical research company’s stock after selling 1,338 shares during the period. Mutual of America Capital Management LLC’s holdings in Edwards Lifesciences were worth $5,271,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Rosenberg Matthew Hamilton bought a new stake in shares of Edwards Lifesciences during the 2nd quarter valued at $28,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $26,000. SouthState Corp purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $27,000. Rossby Financial LCC purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $29,000. Finally, Costello Asset Management INC purchased a new position in shares of Edwards Lifesciences during the 1st quarter valued at $29,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $76.03 on Wednesday. The stock has a 50 day moving average of $77.46 and a 200 day moving average of $76.25. Edwards Lifesciences Corporation has a 12 month low of $64.89 and a 12 month high of $83.00. The firm has a market cap of $44.64 billion, a PE ratio of 10.94, a PEG ratio of 3.61 and a beta of 1.05. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the company earned $0.70 earnings per share. The firm’s revenue was up 11.9% on a year-over-year basis. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on EW shares. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $85.00 to $89.00 and gave the company an “outperform” rating in a research note on Friday, July 25th. Truist Financial lifted their target price on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the company a “hold” rating in a research note on Friday, July 25th. The Goldman Sachs Group restated a “buy” rating on shares of Edwards Lifesciences in a research note on Friday, July 25th. Barclays lifted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an “overweight” rating in a research note on Friday, July 25th. Finally, Argus upgraded shares of Edwards Lifesciences to a “strong-buy” rating in a research note on Thursday, July 10th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.06.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel J. Lippis sold 4,114 shares of the company’s stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the sale, the vice president owned 22,002 shares in the company, valued at $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is currently owned by corporate insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.